EXEL
Exelixis, Inc.NASDAQHealthcare$43.88-0.36%ClosedMarket Cap: $11.76B
As of 2026-04-06
Valuation
P/E (TTM)
15.03
PEG
0.30
P/B
5.51
P/S
5.07
EV/EBITDA
12.26
DCF Value
$228.48
FCF Yield
7.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.4%
Operating Margin
37.6%
Net Margin
33.7%
ROE
36.9%
ROA
28.1%
ROIC
29.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $598.7M | 95.6% | $235.2M | $244.5M | $0.88 | — |
| FY 2025 | $2.32B | 96.4% | $872.2M | $782.6M | $2.78 | — |
| Q3 2025 | $597.8M | 96.9% | $236.5M | $193.6M | $0.70 | — |
| Q2 2025 | $568.3M | 96.6% | $213.6M | $184.8M | $0.65 | — |
| Q1 2025 | $555.4M | 96.5% | $186.9M | $159.6M | $0.55 | — |
| FY 2024 | $2.17B | 96.5% | $604.6M | $521.3M | $1.76 | — |
| Q4 2024 | $566.8M | 96.5% | $163.2M | $139.9M | $0.47 | — |
| Q3 2024 | $539.5M | 96.8% | $136.1M | $118.0M | $0.40 | — |
| Q2 2024 | $637.2M | 97.2% | $275.9M | $226.1M | $0.77 | — |
| Q1 2024 | $425.2M | 95.0% | $29.5M | $37.3M | $0.12 | — |
| Q4 2023 | $479.7M | 95.5% | $81.8M | $85.5M | $0.27 | — |
| FY 2023 | $1.83B | 96.0% | $170.9M | $207.8M | $0.65 | — |